We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Isis Pharmaceuticals Earns $2.15M
News

Isis Pharmaceuticals Earns $2.15M

Isis Pharmaceuticals Earns $2.15M
News

Isis Pharmaceuticals Earns $2.15M

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Isis Pharmaceuticals Earns $2.15M"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Isis Pharmaceuticals, Inc. has announced that it has earned a $2.15 million milestone payment from Biogen related to advancing the ongoing pivotal Phase 3 study (CHERISH) evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA). To date, Isis has generated more than $120 million in payments from Biogen related to the development of ISIS-SMNRx.

CHERISH, a Phase 3 study of ISIS-SMNRx, is a randomized, double-blind, sham-procedure controlled fifteen month study in approximately 120 children who are non-ambulatory with SMA between the ages of 2 to 12.

The study will evaluate the efficacy and safety of 12 mg doses of ISIS-SMNRx with a primary endpoint of a change in the Hammersmith Functional Motor Scale-Expanded (HFMSE), a validated method to measure changes in muscle function in patients with SMA. Additional efficacy endpoints are also included in the study.

Advertisement